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Abstract
Background:  Reovirus type 3 Dearing strain (ReoT3D) has an inherent propensity to
preferentially infect and destroy cancer cells. The oncolytic activity of ReoT3D as a single agent has
been demonstrated in vitro and in vivo against various cancers, including colon, pancreatic, ovarian
and breast cancers. Its human safety and potential efficacy are currently being investigated in early
clinical trials. In this study, we investigated the in vitro combination effects of ReoT3D and
chemotherapeutic agents against human non-small cell lung cancer (NSCLC).
Results: ReoT3D alone exerted significant cytolytic activity in 7 of 9 NSCLC cell lines examined,
with the 50% effective dose, defined as the initial virus dose to achieve 50% cell killing after 48 hours
of infection, ranging from 1.46 ± 0.12 ~2.68 ± 0.25 (mean ± SD) log10 pfu/cell. Chou-Talalay analysis
of the combination of ReoT3D with cisplatin, gemcitabine, or vinblastine demonstrated strong
synergistic effects on cell killing, but only in cell lines that were sensitive to these compounds. In
contrast, the combination of ReoT3D and paclitaxel was invariably synergistic in all cell lines tested,
regardless of their levels of sensitivity to either agent. Treatment of NSCLC cell lines with the
ReoT3D-paclitaxel combination resulted in increased poly (ADP-ribose) polymerase cleavage and
caspase activity compared to single therapy, indicating enhanced apoptosis induction in dually
treated NSCLC cells. NSCLC cells treated with the ReoT3D-paclitaxel combination showed
increased proportions of mitotic and apoptotic cells, and a more pronounced level of caspase-3
activation was demonstrated in mitotically arrested cells.
Conclusion: These data suggest that the oncolytic activity of ReoT3D can be potentiated by
taxanes and other chemotherapeutic agents, and that the ReoT3D-taxane combination most
effectively achieves synergy through accelerated apoptosis triggered by prolonged mitotic arrest.
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Background
The use of viral vectors for cancer gene therapy has been
vigorously explored for the last two decades. The overall
goal of the strategy is to promote cancer cell death
through various means, such as tumor suppressor gene
replacement, oncogene inactivation, suicide gene deliv-
ery, drug sensitization or enhancement of anticancer
immunity. The extensive research efforts to develop tumor
cell death-inducing viral vectors have reignited the interest
in oncolytic viruses in recent years as a promising group of
viral therapeutics that can directly induce tumor cell lysis
through viral replication. The latest multidisciplinary
research in cancer genomics and proteomics further pro-
vides an opportunity to discern various molecular path-
ways specifically upregulated (or dysregulated) in cancers
that can be exploited as part of viral replication and
destruction machinery. Indeed, many replication-compe-
tent oncolytic viruses currently in development are recom-
binant viruses engineered to become reliant on such
cancer-specific molecules and signaling pathways for viral
entry and replication, thus rendering cancer cells more
selectively susceptible to virus-mediated oncolysis [1].
Unlike chemical entity-based anticancer agents, these
viruses can propagate in susceptible tumor cells, re-target,
infect, and destroy remaining cancer cells within the pri-
mary tumor or in the metastases, repeating the cycle until
viral spread is halted by the host antiviral response or by
mechanical barriers such as loss of vasculature and
necrotic tissues.
Mammalian reoviruses are ubiquitous, non-enveloped
dsRNA viruses, normally associated with relatively benign
pathology in humans. The Dearing strain of reovirus sero-
type 3 (ReoT3D) is a non-engineered wild type reoviral
strain and belongs to a growing number of the new gener-
ation of oncolytic viruses because of its innate ability to
preferentially kill transformed cells [2,3]. The oncolytic
potency of ReoT3D has been extensively demonstrated
against various cancers in vitro and  in vivo, including
colon, pancreatic, ovarian and breast cancers, as well as
malignant gliomas and lymphoid malignancies [4-9]. The
safety, feasibility and potential efficacy of ReoT3D cancer
therapy are currently being investigated in phase I/II clin-
ical trials [10]. As with other emerging therapeutics for
cancer, the combined regimen of ReoT3D and conven-
tional chemotherapeutic agents is expected to play a sig-
nificant role in future clinical applications. However, it is
currently unknown whether conventional chemothera-
peutic agents can augment or interfere with the oncolytic
effect of ReoT3D. In this study, we evaluated the oncolytic
activity of ReoT3D in non-small cell lung cancer




Oncolytic activity of ReoT3D and progeny virion 
production in NSCLC cell lines
We first examined the in vitro susceptibility of human
NSCLC cell lines to ReoT3D, as reoviral oncolytic activity
had not been extensively studied in human lung cancer
cells. Nine NSCLC cell lines (NCI-H460, A549/ATCC,
HOP-62, NCIH322M, NCI-H226, EKVX, NCI-H23, NCI-
H522, and HOP-92) included in the NCI-60 tumor cell
line panel (Developmental Therapeutics Program, DTP,
NCI-Frederick, Frederick, MD) were incubated with seri-
ally diluted ReoT3D for cytopathic effect (CPE) determi-
nation. Within 48 hours post-infection, ReoT3D induced
significant cell death in seven of nine NSCLC cell lines in
a dose-dependent manner (Figure 1). ReoT3D 50 percent
effective dose (ED50), defined as the initial virus dose
(multiplicity of infection, MOI, expressed in plaque form-
ing units per cell, pfu/cell) that resulted in 50% cell viabil-
ity at 48 hours post-inoculation as compared to untreated
controls, ranged from 1.46 ± 0.12 to 2.68 ± 0.25 (mean ±
SD from 3 separate experiments) log10 pfu/cell in the sen-
sitive cell lines (Table 1). In contrast, NCI-H226 and NCI-
H322M were relatively resistant to ReoT3D in this short-
term incubation assay, as indicated by the significantly
lower levels of cell death even at the highest inoculum
dose compared to those seen in the sensitive cell lines (P
< 0.0001) (Figure 1). While ReoT3D has been shown to
induce CPE in murine cells with an activated Ras pathway
[11,12], the presence of Ras-activating gene mutations
[13] or activated Ras was not necessarily associated with
lower ReoT3D ED50 in the NSCLC cell lines tested in our
study (Table 1 and Figure 2).
In vitro combination effects of ReoT3D and 
chemotherapeutic agents against NSCLC cells
Next, we investigated the combination effects of ReoT3D
and chemotherapeutic agents in four ReoT3D-susceptible
(NCI-H460, HOP-92, NCIH23, and EKVX) and two rela-
tively resistant (NCI-H226 and NCI-H322M) cell lines
using the Chou-Talalay method. Growth inhibitory effects
of chemotherapeutic agents, paclitaxel, cisplatin, gemcit-
abine, and vinblastine, were first determined in each cell
line by the XTT cytotoxicity assay and expressed as the
drug concentration that inhibited cell growth by 50%
compared to untreated control (IC50) (Table 2). Of the 6
cell lines, NCI-H322M and EKVX showed high levels of
resistance to multiple compounds, consistent with the
previous report that characterized them as multi-drug
resistant against a variety of anticancer agents [14] (Table
2). When NCI-H460 cells were incubated with increasing
doses of ReoT3D in the absence or presence of paclitaxel,
whose concentration was serially increased to maintain a
constant ratio to the ReoT3D dosage (the constant ratio
combination design) [15], the synergistic anticancer effect
of the two agents was clearly demonstrated by a leftwardMolecular Cancer 2009, 8:47 http://www.molecular-cancer.com/content/8/1/47
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shift of the dose response curve (Figure 3a) as well as iso-
bologram and combination index (CI) analyses [16,17]
(Figure 3b and 3c, respectively). The combination effects
of ReoT3D and other chemotherapeutic agents were simi-
larly examined in all 6 cell lines using at least two different
dosage ratios, and CI values were obtained for each com-
bination regimen (Table 2). In many instances, the com-
bination of ReoT3D with different chemotherapeutic
agents was found to exert moderate to strong synergistic
effects at both combination ratios as shown by the CI that
were consistently smaller than 1.0 at ED50, ED75 and
ED90 (Table 2). Interestingly, with the exception of
ReoT3D-paclitaxel combination, antagonistic effects (CI >
1.0) of ReoT3D-chemotherapeutic combinations were
typically observed in NSCLC cell lines that exhibited high-
level resistance to the test compounds with IC50 often
exceeding the highest test concentration, 100 μM (Table
2). In contrast, the combination of ReoT3D and paclitaxel
was consistently synergistic in all the NSCLC cell lines
tested, regardless of the level of paclitaxel sensitivity
(Table 2). The relative resistance of NSCLC cell lines to
ReoT3D did not appear to negatively influence the out-
comes, as the synergistic effect was clearly seen in NCI-
H226 for all the combination regimens examined (Table
2).
These data demonstrated that while the oncolytic activity
of ReoT3D could be generally potentiated by the chemo-
therapeutic agents that alone were cytotoxic to the tested
cell lines, paclitaxel appeared to exert unique effects on
the cell-death process induced by ReoT3D, even in the
cells with reduced sensitivity to the compound.
Progeny virion production from NSCLC cells treated with 
the combination of ReoT3D and chemotherapeutic agents
Next, we asked whether the synergistic oncolytic effects of
ReoT3D-chemotherapeutic combination regimens
reflected increases in virally induced lytic cell death,
driven by a burst of progeny virion production from the
cells. To capture early changes in viral production levels,
the amounts of infectious virions released into the culture
supernatants in the first 24 hours were compared among
Oncolytic effect of reovirus type 3 Dearing strain (ReoT3D) in non-small cell lung cancer (NSCLC) cells Figure 1
Oncolytic effect of reovirus type 3 Dearing strain (ReoT3D) in non-small cell lung cancer (NSCLC) cells. Dose-
dependent cell death shown as % cell survival (mean ± SD) induced by ReoT3D in 9 NSCLC cell lines evaluated by the XTT 
assay [49] at 48 hours post-infection. ReoT3D dose is defined as multiplicity of infection (MOI) expressed in plaque forming 
units per cell (pfu/cell). The curves were fitted by non-linear regression using GraphPad Prism (GraphPad Software, Inc., San 
Diego) for 7 permissive cell lines, NCI-H460, A549/ATCC, HOP-62, EKVX, NCI-H23, NCI-H522, and HOP-92. The data 
shown are representative of 3 separate experiments.Molecular Cancer 2009, 8:47 http://www.molecular-cancer.com/content/8/1/47
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NSCLC cell lines infected with ReoT3D in the absence or
presence of different chemotherapeutic agents. Notably,
the addition of paclitaxel to ReoT3D (MOI = 20) was
found to increase the level of progeny virion production
as compared to virus alone in all 4 cell lines tested, NCI-
H460, NCI-H23, EKVX and HOP-92 (P  = 0.001, 0.03,
0.003 and 0.0001, respectively) (Figure 4a). However,
such augmentation of virion production was not unique
to paclitaxel nor associated with synergy, as ReoT3D-vin-
blastine combination also significantly increased the level
of progeny virions released from EKVX and NCI-H322M
(P < 0.01) (Figure 4b), where the combination was not
associated with a synergistic effect (mean CI > 1.0). In
contrast to paclitaxel and vinblastine, the addition of
gemcitabine was not associated with an increased reoviral
progeny virion production in NSCLC cells (Figure 4b).
These data suggested that the synergistic effects of
ReoT3D-chemotherapeutic combinations did not directly
result from lytic necrosis induced by rapid increases in vir-
ion release, but probably stemmed from certain changes
in programmed cell death pathways.
PARP cleavage in NSCLC cells treated with ReoT3D-
chemotherapeutic combination regimens
Reovirus type 3 Abney (ReoT3A) has been shown to
induce apoptotic cell death in various cancer cell lines,
including in 2 NSCLC cell lines, NCI-H157 and A549
[18]. To further investigate the mechanistic basis for the
synergistic activity of ReoT3D-chemotherapeutic combi-
nations in NSCLC cells, we examined the proteolytic
cleavage of poly (ADP-ribose) polymerase (PARP) in NCI-
H460 treated with 20 MOI of ReoT3D alone or in combi-
nation with gemcitabine, paclitaxel or vinblastine for 24
to 30 hours. Western blot analysis of cell lysates demon-
strated the cleaved 89-kDa PARP fragment in ReoT3D-
treated NCI-H460, whereas treatment with gemicitabine
(1 μM), paclitaxel (1 μM) or vinblastine (0.1 μM) alone
resulted in virtually undetectable PARP cleavage in this
cell line (Figure 5). Cells treated with the combination of
ReoT3D and paclitaxel showed significantly higher levels
of PARP cleavage than ReoT3D alone at 24 and 30 hours
post-treatment, accompanied by a gradual decrease in the
amount of full-length PARP (Figure 5). Increased PARP
cleavage was also observed with the combination of
ReoT3D and other chemotherapeutic agents at 24 or 30
hours post-treatment, although to a lesser extent than
ReoT3D-paclitaxel combination (Figure 5). These data
suggested that the synergistic cell death induced by the
ReoT3D-paclitaxel combination was mediated at least in
part by the enhanced apoptotic process in NCI-H460.
Activation of caspases in NSCLC cells treated with 
ReoT3D alone or in combination with paclitaxel
To explore whether the enhancement of apoptosis played
a role in the synergistic activity of the ReoT3D-paclitaxel
combination in other NSCLC cell lines, we examined the
level of caspase activity in NCI-H460, NCI-H23, EKVX
and NCI-H322M treated with increasing doses of either
ReoT3D or paclitaxel alone or both in combination, using
the constant ratio combination design [15], the same dos-
ing scheme adopted for CI analyses of Chou-Talalay (see
above). In each of 4 cell lines, treatment with ReoT3D
alone led to a significant increase in caspase activity in a
dose-dependent manner, although the response appeared
less robust in NCI-H322M, where higher ReoT3D MOIs
were required to achieve similar magnitudes of caspase
activation above baseline than in 3 other cell lines (Figure
6a). The increases in caspase activity were associated with
Levels of GTP-bound activated Ras protein in 9 NSCLC cell  lines analyzed by Western blot, using anti-pan-Ras antibody Figure 2
Levels of GTP-bound activated Ras protein in 9 
NSCLC cell lines analyzed by Western blot, using 
anti-pan-Ras antibody. Note, high levels of activated Ras 
were observed with A549/ATCC (K-rasG12S) [13], HOP-62 
(K-rasG12C) [13], and NCI-H23 (K-rasG12C) [13], followed by 
NCI-H460 (K-rasQ61H) [13], EKVX and HOP-92. The levels 
of activated Ras were significantly lower not only with 
ReoT3D-resistant NCI-H322M and NCI-H226, but also with 
ReoT3D sensitive cell line, NCI-H522. Also see table 1 for 
comparison of Ras-activating gene mutation status and 
ReoT3D sensitivity of each cell line.
Table 1: Oncolytic activity of ReoT3D in 9 NSCLC cell lines 
included in the NCI-60 cell line panel
NSCLC Cell Line ED50 (log10 pfu/cell: mean ± SD)
NCI-H460* 2.68 ± 0.25
A549/ATCC* 2.51 ± 0.27
HOP-62* 2.56 ± 0.19
NCI-H322M > 3.30
NCI-H226 > 3.30
EKVX 2.47 ± 0.34
NCI-H23* 2.47 ± 0.15
NCI-H522 1.46 ± 0.12
HOP-92 1.96 ± 0.27
ED50: 50% effective dose defined by the initial MOI (pfu/cell) to 
achieve 50% cell death in 48 hours after infection. Shown are mean ± 
SD from 3 independent experiments. *Asterisk denotes cell lines with 
ras gene mutation. Abbreviations: ReoT3D, reovirus type 3 Dearing; 
NSCLC, non-small cell lung cancer; MOI, multiplicity of infection; pfu, 
plaque forming units.Molecular Cancer 2009, 8:47 http://www.molecular-cancer.com/content/8/1/47
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dose-dependent decreases in cell viability as assessed by
intracellular ATP content in ReoT3D-treated cells (Figure
6a). Paclitaxel alone had virtually no effects on caspase
activation or ATP content during the 24-hr exposure,
except in NCI-H23 that showed moderate increases in cas-
pase activity upon treatment with the compound at ≥ 10
nM (Figure 6a). When ReoT3D was combined with pacli-
taxel, the levels of caspase activation appeared more pro-
nounced as compared to ReoT3D single therapy, as seen
by a leftward shift of the dose response curves (Figure 6a).
Similar results were obtained from 3 separate experiments
for all 4 cell lines.
In order to evaluate whether the extent of caspase activa-
tion induced by the ReoT3D-paclitaxel combination was
significantly different from ReoT3D single treatment in
these cell lines, the caspase activity dose-response curves
were fitted by non-linear regression using GraphPad
Prism (GraphPad Software Inc., San Diego, CA) (Figure
6b). The best-fit values of a variable, LogEC50, obtained
by the Prism analysis from 3 independent experiments
were then compared between the two treatment regimens,
ReoT3D alone vs. ReoT3D-paclitaxel combination, using
a paired t-test. The analysis demonstrated that the activa-
tion of caspases was significantly enhanced with the
ReoT3D-paclitaxel combination therapy as compared to
ReoT3D alone in NCI-H460, NCI-H23, EKVX and
NCIH322M (P  = 0.004, 0.03, 0.04, and 0.02, respec-
tively). These data suggested that enhanced apoptotic cell
death most likely constituted the synergistic cell killing
induced by the combination of ReoT3D and paclitaxel in
NSCLC cells.
Synergistic activity of ReoT3D and paclitaxel combination in NCI-H460 cells Figure 3
Synergistic activity of ReoT3D and paclitaxel combination in NCI-H460 cells as demonstrated by (a) the leftward 
shift of the dose response curve (error bars: SD), (b) isobologram analysis (shown are for the ED50 doses), and (c) fractional 
effect-combination index (CI) plot generated by CalcuSyn (Biosoft, Ferguson, MO). The data shown are representative of 3 
separate experiments.Molecular Cancer 2009, 8:47 http://www.molecular-cancer.com/content/8/1/47
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Dynamic effects of ReoT3D and paclitaxel on cell cycle 
progression and caspase activation
ReoT3D infection has been shown to induce cell cycle
arrest at G1/S and G2/M [19,20]. Antimicrotubule agents,
including taxanes and vinca alkaloids, activate the spin-
dle-assembly checkpoint and induce mitotic arrest at the
metaphase and anaphase transition, which ultimately
leads to cell death by apoptosis [21]. A certain proportion
of cells exposed to these antimitotic agents may undergo
an aberrant mitotic exit without cytokinesis, forming
multinucleated cells in interphase [21]. To gain mechanis-
tic insight into the enhanced apoptotic cell death induced
by the ReoT3D-paclitaxel combination, we investigated
the effects of ReoT3D and paclitaxel on cell cycle and cas-
pase-3 activation in NSCLC cells using flow cytometry.
NCI-H23 cells were incubated with either ReoT3D (20
MOI) or paclitaxel (0.1 or 1 μM) alone or both in combi-
nation for 24 hours, after which non-adherent (detached)
and adherent cells were harvested and evaluated for active
caspase- 3 expression and DNA content. The total number
of viable cells was obtained by the trypan blue dye exclu-
sion method. Consistent with the caspase activity assay
data (see above), incubation of NCI-H23 with ReoT3D
resulted in an increased population of cells positive for
cleaved active caspase-3 [22] as compared to untreated
control (Figure 7a). DNA content analysis by propidium
iodide (PI) staining demonstrated that the active caspase-
3-expressing cells were equally distributed between G1
(2N DNA content) and G2/M phases (4N) after ReoT3D
exposure (Figure 7a). In contrast, treatment with 0.1 or 1
μM paclitaxel led to marked increases in post-G1 cell pop-
ulations, in particular cells with DNA content of 4N or
greater (≥ 4N), and more than a third of these post-G1
cells with ≥ 4N DNA content were positive for activated
caspase-3 (Figure 7a). In addition, paclitaxel treatment
triggered an increase in the subdiploid (sub-2N) cell pop-
ulation, indicative of late apoptosis, in NCI-H23 cells
(Figure 7a). The combination of ReoT3D and paclitaxel
significantly decreased the number of viable cells (data
Table 2: Combination index values for ReoT3D-chemotherapeutic combination regimens in NSCLC cells
Combination Index Values§ Combination Index Values§
Drugs & Cell Lines Drug Sensitivity¶ IC50 
(μM)
Ratio* I ED50 ED75 ED90 Mean Ratio* II ED50 ED75 ED90 Mean
Paclitaxel
NCI-H460 0.003 ± 0.001 1:53 0.903 0.221 0.057 0.394 1:533 0.193 0.042 0.013 0.083
HOP-92 38.50 ± 16.01 1:20 0.144 0.295 0.613 0.351 1:200 0.178 0.420 0.994 0.530
NCI-H23 0.08 ± 0.04 1:20 0.577 0.303 0.159 0.347 1:200 0.329 0.061 0.011 0.134
EKVX 56.06 ± 15.87 1:20 0.294 0.440 0.660 0.464 1:200 0.124 0.216 0.374 0.238
NCI-H226 77.79 ± 25.08 1:20 0.543 0.344 0.218 0.368 1:200 0.004 1.30E-04 4.73E-06 0.001
NCI-H322M > 100 1:20 0.069 0.092 0.133 0.098 1:200 0.078 0.081 0.084 0.081
Cisplatin
NCI-H460 5.31 ± 1.21 1:53 0.875 0.313 0.112 0.433 1:533 0.661 0.292 0.129 0.361
HOP-92 6.82 ± 3.22 1:20 0.352 0.325 0.500 0.392 1:200 0.053 0.080 0.195 0.109
NCI-H23 3.51 ± 1.15 1:20 0.579 0.487 0.530 0.532 1:200 0.546 0.248 0.342 0.379
EKVX 29.34 ± 6.62 1:20 0.955 0.559 0.328 0.614 1:200 0.933 0.754 0.610 0.766
NCI-H226 14.71 ± 6.60 1:20 0.615 0.297 0.145 0.352 1:200 0.558 0.081 0.013 0.217
NCI-H322M > 100 1:20 > 10 > 10 > 10 > 10 1:200 > 10 > 10 > 10 > 10
Gemcitabine
NCI-H460 0.01 ± 0.003 1:53 0.199 0.126 0.126 0.150 1:533 0.006 0.017 0.054 0.025
HOP-92 0.83 ± 0.61 1:20 0.372 0.117 0.047 0.179 1:200 0.099 0.110 0.127 0.112
NCI-H23 0.02 ± 0.01 1:20 0.630 0.249 0.285 0.388 1:200 0.207 0.092 0.369 0.223
EKVX > 100 1:20 > 10 > 10 > 10 > 10 1:200 > 10 > 10 > 10 > 10
NCI-H226 17.69 ± 10.16 1:20 0.112 0.030 0.008 0.050 1:200 0.057 0.007 0.001 0.021
NCI-H322M > 100 1:20 > 10 > 10 > 10 > 10 1:200 > 10 > 10 > 10 > 10
Vinblastine
NCI-H460 0.92 ± 0.35 (nM) 1:5.3 0.255 0.149 0.089 0.164 1:53.3 0.069 0.045 0.031 0.049
HOP-92 48.80 ± 23.08 1:20 1.749 7.049 > 10 > 10 1:200 0.133 1.256 11.922 4.437
NCI-H23 1.49 ± 1.09 (nM) 1:2 0.316 0.056 0.019 0.130 1:20 0.367 0.052 0.008 0.142
EKVX > 100 1:20 3.275 1.927 1.134 2.112 1:200 0.193 0.651 2.192 1.012
NCI-H226 28.46 ± 14.13 1:20 0.081 0.043 0.023 0.049 1:200 0.027 0.006 0.001 0.012
NCI-H322M > 100 1:20 > 10 > 10 > 10 > 10 1:200 > 10 > 10 > 10 > 10
¶Sensitivities of 6 NSCLC cell lines to each listed drug tested as a single agent (mean ± SD from 3 separate experiments). *Constant ratios of drug 
concentrations in μM (or nM) and ReoT3D MOI doses in plaque forming units per cell used for combination studies (see text). §Combination index 
(CI) values shown are from representative experiments repeated three times with similar results. Abbreviations: ReoT3D, reovirus type 3 Dearing; 
NSCLC, non-small cell lung cancer; IC50, 50% inhibitory concentration; MOI, multiplicity of infection expressed in plaque forming units per cell.Molecular Cancer 2009, 8:47 http://www.molecular-cancer.com/content/8/1/47
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not shown), while increasing the proportion of cells
expressing active caspase-3, in particular in post-G1
phase, compared to ReoT3D- or paclitaxel-single treat-
ment (Figure 7a).
Similar effects of ReoT3D-paclitaxel combination on cell
cycle and apoptosis induction were also demonstrated in
3 other NSCLC cell lines, NCIH460, EKVX and NCI-
H322M (Figure 7b). Paclitaxel treatment invariably
increased the proportion of post-G1 cells in these cell
lines, although the percentages of cells positive for acti-
vated caspase-3 were significantly smaller than in NCI-
H23. The ReoT3D-paclitaxel combination consistently led
to substantial increases in cells expressing active caspase-
3, including in paclitaxel-resistant EKVX and NCI-H322M
cells, and these increases appeared more prominent in
post-G1 phase (Figure 7b). Indeed, statistical analysis
demonstrated that the proportions of active caspase-3-
positive cells were significantly different among the treat-
ment groups in the post-G1 cell population (P < 0.005,
one-way ANOVA), but not in the population with DNA
content of 2N or less (sub-G1 and G1) (P = 0.05). In this
subpopulation of post-G1 cells, the proportions of active
caspase-3-expressing cells were significantly increased
with the ReoT3D-paclitaxel combination treatment as
compared to single therapy (P = 0.02 for both between-
group comparisons, ReoT3D alone vs. ReoT3D+paclitaxel
0.1 μM, and paclitaxel 0.1 μM alone vs. ReoT3D+paclit-
axel 0.1 μM; P = 0.02 and < 0.04 for between ReoT3D
alone vs. ReoT3D+paclitaxel 1 μM, and paclitaxel 1 μM
alone vs. ReoT3D+paclitaxel 1 μM, respectively). These
data suggested that the combination of ReoT3D and pacl-
itaxel enhanced apoptotic cell death, which was linked to
cell cycle perturbation in NSCLC cells.
Ultrastructural analysis of NSCLC cells treated with 
ReoT3D and paclitaxel
To further examine the relationship between cell cycle
perturbation and apoptotic cell death induced by ReoT3D
and paclitaxel, we examined the morphological changes
of NCI-H23 cells treated with either ReoT3D or paclitaxel
alone or in combination, using electron microscopy
(EM). After overnight (~20 hours) treatment, the cells
were directly fixed in situ and processed for the analysis.
The EM study did not include dead cells that had detached
before fixation. One hundred cells were surveyed within
one 60-nm thin section for each treatment group to docu-
ment significant changes as compared to untreated con-
trol (Table 3). When NCI-H23 cells were exposed to 1 μM
paclitaxel overnight, an increased number of cells were
(a) Fold increases (mean ± SD) in infectious progeny virion production Figure 4
(a) Fold increases (mean ± SD) in infectious progeny virion production determined by plaque assay in NCI-H460, 
NCI-H23, EKVX and HOP-92 treated with the combination of ReoT3D (MOI = 20) and paclitaxel (1 μM for NCI-H460 and 
NCI-H23 and 10 μM for EKVX and HOP-92 cells) for 24 hours as compared to ReoT3D alone (MOI = 20). Paclitaxel invariably 
increased the level of virion production from all the cell lines tested. (b) Fold increases (mean ± SD) in infectious progeny vir-
ion production in NCI-H23, EKVX and NCI-H322M treated with ReoT3D (MOI = 20) in combination with paclitaxel (0.1 μM 
for NCI-H23 and 1 μM for EKVX and NCI-H322M), gemcitabine (0.1 μM for NCI-H23 and 1 μM for EKVX and NCI-H322M) 
or vinblastine (10 nM for NCI-H23 and 100 nM for EKVX and NCI-H322M) for 24 hours as compared to ReoT3D alone (MOI 
= 20). Note the increased virion production in the presence of tubulin-binding agents, paclitaxel or vinblastine, but not with 
gemcitabine. Asterisks denote statistical significance (P < 0.05).Molecular Cancer 2009, 8:47 http://www.molecular-cancer.com/content/8/1/47
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found to be enlarged and multinucleated (Figure 8b), as
verified by the survey (Table 3). These multinucleated
cells, detected as post-G1 cells with ≥ 4N DNA content by
flow cytometry (Figure 7a and 7b), represented the cells
that had exited mitosis without cytokinesis. The cells
infected with ReoT3D (MOI = 20) contained numerous
viral particles, mostly in viral inclusion bodies that
appeared globular in shape, and an increased number of
mitochondria (Figure 8c and 8d). The combination of
ReoT3D and paclitaxel resulted in notable increases in
mitotic cells (Figure 8e), and apoptotic cells characterized
by condensed and fragmented chromatin as well as cyto-
plasmic shrinkage and vacuolation (Figure 8f) (Table 3).
Of note, although the number of viral particle-harboring
cells that could be detected in the EM specimen was
decreased with the ReoT3D-paclitaxel combination com-
pared to ReoT3D alone (Table 3), the level of infectious
progeny virion in the corresponding supernatant was
higher than that of cells treated with ReoT3D alone (data
not shown), indicating that the addition of paclitaxel
enhanced reoviral production as discussed earlier.
These data from flow cytometric and electron microscopic
analyses strongly suggested that treatment with the com-
bination of ReoT3D and paclitaxel caused prolonged
mitotic arrest, which triggered accelerated apoptosis,
resulting in synergistic cell killing in dually treated NSCLC
cells.
Discussion
Lung cancer is the leading cause of cancer mortality in
both men and women in the United States [23] and all
cancer deaths worldwide [24]. The most common form of
lung cancer is NSCLC that includes squamous cell carci-
noma, adenocarcinoma, and large cell carcinoma. Despite
the tremendous efforts and progress in lung cancer
research, treatment outcomes for non-localized NSCLC
remain poor [25]. New treatment strategies are urgently
needed to improve survival for advanced NSCLC patients.
In the current study, we uncovered a potent oncolytic
activity of ReoT3D against a panel of human NSCLC cell
lines, in particular, NSCLC cell lines of adenocarcinoma
or large cell carcinoma origin. The susceptibility of cancer
cells to ReoT3D-mediated cytolysis has been attributed to
increased Ras activity [11,12]. However, we did not
observe any significant association between the ReoT3D-
permissibility and the presence of Ras-activating gene
mutations or activated Ras in human NSCLC cells. The
lack of association has also been reported by others in
human colon cancers [26]. It is possible that in addition
to the activation status of Ras-associated pathways
[11,12], there are other molecular determinants of
ReoT3D-sensitivity, such as the cell surface density of
putative ReoT3D receptors/coreceptors [27-29] and intra-
cellular virion uncoating processes [30,31], all of which
can affect ReoT3D infection efficiency.
The combination effects of herpesvirus or adenovirus-
based oncolytic viral vectors and chemotherapeutic agents
have previously been evaluated against different human
cancers [32-37]. Synergistic activity was reported in the
majority of these studies. However, combination regi-
mens selected for the previous studies were mostly limited
in scope in terms of dose range and the number of chem-
otherapeutic agents investigated. In the current study, we
demonstrated that the oncolytic activity of ReoT3D
against NSCLC cells could be significantly potentiated by
a number of chemotherapeutic agents used in the treat-
ment of NSCLC, including paclitaxel, cisplatin, gemcitab-
ine and vinblastine. Combination analysis based on the
Chou-Talalay's method [16,17] clearly showed significant
levels of synergy between ReoT3D and each chemothera-
peutic agent tested. Interestingly, we found that the drug
sensitivity of each NSCLC cell line was an important
determinant for the in vitro synergistic effect of ReoT3D-
chemotherapeutic combination regimens, with the excep-
tion of ReoT3D-paclitaxel combination. It is conceivable
that certain molecular changes conferring drug resistance
can antagonize the process of ReoT3D-mediated cell kill-
ing. Our data, therefore, caution against the use of chem-
otherapeutic agents combined with ReoT3D for the
Western blot analysis of poly (ADP-ribose) polymerase  (PARP) cleavage Figure 5
Western blot analysis of poly (ADP-ribose) polymer-
ase (PARP) cleavage in cell lysates obtained from NCI-
H460 cultured for 24 to 30 hrs after infection with ReoT3D 
(MOI = 20) in the absence or presence of gemcitabine (1 
μM), paclitaxel (1 μM) or vinblastine (0.1 μM). Shown are the 
full-length PARP (116 kDa) and the larger fragment (89 kDa) 
of apoptotically cleaved products, as well as β-actin used as a 
loading control. Results are representative of 2 separate 
experiments.Molecular Cancer 2009, 8:47 http://www.molecular-cancer.com/content/8/1/47
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treatment of NSCLC that have developed resistance to the
agents. In contrast, the level of ReoT3D sensitivity did not
appear to compromise the combination effects in NSCLC
cells. Rather, the addition of chemotherapeutic agents
may help accelerate ReoT3D-induced cell death process,
which is otherwise slowed in NSCLC cells with low sus-
ceptibility to ReoT3D infection.
The most intriguing finding from our study was the syner-
gistic effect of ReoT3D-paclitaxel combination consist-
ently observed in all the NSCLC cell lines examined,
regardless of the level of sensitivity to the compound.
Because previous studies of oncolytic virus-chemothera-
peutic combinations, in particular with paclitaxel, did not
address the impact of drug resistance on the combination
effects, we cannot ascertain whether our finding is unique
to reovirus-containing combination therapy. Mammalian
reoviruses are known to exploit microtubules for the for-
mation of viral replication complexes (inclusion bodies)
[38]. Based on our initial findings that the addition of
paclitaxel to ReoT3D significantly increased the level of
progeny virion production from all the NSCLC cell lines
(a) Levels of caspase activity and ATP content in NCI-H460, NCI-H23, EKVX and NCI-H322M cells[] Figure 6
(a) Levels of caspase activity and ATP content in NCI-H460, NCI-H23, EKVX and NCI-H322M cells treated with 
increasing doses of either ReoT3D or paclitaxel alone, or both in combination for 24 hours, using the constant ratio combina-
tion design [15]. This design format was employed to evaluate the synergistic activity of ReoT3D-chemotherapeutic combina-
tion regimens (see text). Shown are the mean ± SD in relative fluorescence units (RFU) and relative luminescence units (RLU) 
for caspase activity (closed triangle) and ATP content (open circle), respectively, for ReoT3D alone (green), ReoT3D-paclitaxel 
combination (red) and paclitaxel alone (blue). The data shown are representative of 3 separate experiments. (b) Dose-
response curves of caspase activation induced by treatment with ReoT3D alone or ReoT3D-paclitaxel combination for 
24 hours fitted by non-linear regression using GraphPad Prism (GraphPad Software, Inc.). Shown as an example are non-linear 
regression analyses for NCI-H460 and EKVX. See text for statistical analysis on the best-fit values.Molecular Cancer 2009, 8:47 http://www.molecular-cancer.com/content/8/1/47
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tested, we speculated that microtubule-stabilizing paclit-
axel might have enhanced reoviral replication, resulting in
a more efficient and synergistic oncolytic effect. However,
the increased progeny virion production was not necessar-
ily a unique outcome of ReoT3D-paclitaxel combination,
but was also observed with ReoT3D-vinblastine combina-
tion in vinblastine-resistant NCI-H322M cells, where the
combination of ReoT3D and vinblastine was found to be
strongly antagonistic. Moreover, the addition of gemcit-
abine to ReoT3D treatment was not associated with an
increased progeny virion production, regardless of the
combination effects (synergy or antagonism) attained.
These data suggested that the synergistic effect of ReoT3D
and chemotherapeutic agents was not the direct result of
enhanced lytic cell death, but more likely the manifesta-
tion of accelerated programmed cell death, which was
triggered before virion assembly and release.
Reovirus has been shown to induce apoptotic cell death in
a variety of cell types, including cancer cells [18,39].
Indeed, increased caspase activity and apoptotic cleavage
of PARP were readily detectable in ReoT3D-treated
NSCLC cells within 24 hours in the current study, as has
been shown in ReoT3A-exposed cancer cells [18]. The
combination treatment with ReoT3D and paclitaxel led to
more robust caspase activation than ReoT3D alone with a
significant leftward shift of the dose response curve in
both paclitaxel-sensitive and -resistant NSCLC cell lines,
suggesting that the enhanced apoptosis most likely consti-
tuted the synergistic cell killing by the combination,
regardless of the level of paclitaxel sensitivity. To gain
more insight into the mechanistic basis of accelerated
apoptosis associated with the ReoT3D-paclitaxel combi-
nation, we examined the effects of ReoT3D and paclitaxel
on caspase-3 activation in relation to cell cycle progres-
Flow cytometric analysis of DNA content and caspase-3 activation in NSCLC cells treated with either ReoT3D (MOI = 20) or  paclitaxel alone (0.1 or 1 μM), or both in combination Figure 7
Flow cytometric analysis of DNA content and caspase-3 activation in NSCLC cells treated with either ReoT3D 
(MOI = 20) or paclitaxel alone (0.1 or 1 μM), or both in combination. (a) Shown are scattergrams (top) and histo-
grams (bottom), ungated, of NCI-H23 cells treated with the indicated agent(s) for 24 hours. Harvested cells were fixed, per-
meabilized and stained with FITC-conjugated anti-active caspase-3 antibody followed by PI staining. Each histogram depicts the 
DNA content of cells in G1 (2N) and G2/M (4N), while the scattergrams demonstrate the proportion of cells with activated 
caspase-3 in different cell cycle phases. Values shown in each quadrant of scattergrams represent the percentages of cells. Of 
note, the histograms also show the apoptotic subdiploid peak (sub-2N), especially enhanced in paclitaxel-treated NCI-H23 
cells. (b) The effects of ReoT3D-paclitaxel combination on caspase-3 activation and DNA content were compared among NCI-
H23, NCI-H460, EKVX and NCI-322M. These NSCLC cells were analyzed as described in (a). Shown are the percentages of 
cells positive or negative for activated caspase-3 in sub- G1/G1 or post-G1 phases. The data shown in (a) and (b) are repre-
sentative of 2 experiments.Molecular Cancer 2009, 8:47 http://www.molecular-cancer.com/content/8/1/47
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Transmission electron micrographs of NCI-H23 cells treated with either paclitaxel (1 μM) or ReoT3D (MOI = 20) alone, or  both in combination for 20 hours Figure 8
Transmission electron micrographs of NCI-H23 cells treated with either paclitaxel (1 μM) or ReoT3D (MOI = 
20) alone, or both in combination for 20 hours. Compared to untreated control (a), the increased number of paclitaxel-
treated NCI-H23 cells were found to be enlarged and multinucleated (b), whereas the cells infected with ReoT3D (c and d) 
contained numerous viral particles, mostly in viral inclusion bodies, which appeared globular in shape (black arrows). In addi-
tion, ReoT3D-infected cells appeared to contain an increased number of mitochondria (white arrows). When the cells were 
exposed to the combination of ReoT3D and paclitaxel, there were increased numbers of mitotic cells (e) as well as apoptotic 
cells characterized by condensed chromatin, cytoplasmic shrinkage and vacuolation (f). The results from survey of 100 cells for 
each treatment group are summarized in Table 3. Scale bars: 2 μm for (a), (b), (c), (e) and (f), and 500 nm for (d).Molecular Cancer 2009, 8:47 http://www.molecular-cancer.com/content/8/1/47
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sion. While taxanes and other antimicrotubule agents are
known to activate the spindle checkpoint and induce
mitotic arrest [21], ReoT3D infection has been shown to
effect cell cycle arrest at G1/S and G2/M [19,20]. Because
arrests in cell cycle progression induced by anticancer
agents are commonly followed by apoptosis [40], we
hypothesized that these two agents with differing effects
on cell cycle progression may have synergistically acti-
vated apoptotic pathways in dually treated NSCLC cells.
We found that the proportion of cells expressing activated
caspase-3 was significantly increased by the ReoT3D-pacl-
itaxel combination as compared to either ReoT3D or pacl-
itaxel single treatment in each NSCLC cell line tested.
Interestingly, the activation of caspase-3 was found more
prominent in post-G1 cell population with ≥ 4N DNA
content. Escape from mitotic arrest induced by spindle
poisons such as taxanes and other antimicrotubule agents
is commonly observed in cancer cells with impaired
(weakened) mitotic checkpoint [21,41]. These cells that
prematurely exit mitosis without proper cell division form
large multinucleated cells with DNA content of 4N or
greater, as demonstrated by EM in our study. After such
mitotic slippage, some cells may undergo p53-dependent
apoptosis, while others survive through senescence or
continuing cell cycle (endoreduplication) [42], depend-
ing on the functions of p53, MAP kinase pathways, and
p21-activated kinase [43,44]. In the current study, we
found that NSCLC cells could efficiently escape from
mitotic arrest induced by paclitaxel at 0.1 ~1 μM and sur-
vive at least for the first 24 hours of exposure, with the
exception of NCI-H23 cells that were more prone to apop-
tosis upon paclitaxel exposure than 3 other NSCLC cell
lines examined. While paclitaxel-treated NCIH460 cells
ultimately underwent dramatic cell death after 48 hours,
EKVX and NCI-H322M demonstrated considerable levels
of resistance to paclitaxel-induced CPE. Nonetheless, the
combination of ReoT3D and paclitaxel consistently accel-
erated the apoptotic process in post-G1 cells, including in
paclitaxelresistant EKVX and NCI-H322M cells. This
enhanced apoptosis appeared to have resulted from pro-
longed mitotic arrest, as corroborated by the EM data
demonstrating that treatment with the ReoT3D-paclitaxel
combination resulted in increased numbers of both
mitotically arrested and apoptotic cells while decreasing
the number of multinucleated cells as compared to pacli-
taxel alone.
The molecular mechanism of prolonged mitotic arrest
induced by the ReoT3D-paclitaxel combination has yet to
be elucidated. It is possible that ReoT3D infection may
enhance the mitotic checkpoint activity in cancer cells
with weakened mitotic checkpoint, for example, by upreg-
ulating the expression of mitotic checkpoint proteins
(such as Mad1, Mad2, BubR1/Mad3, Bub1 and Bub3)
[45], Cdk1 and/or cyclin B [45], or suppressing the ana-
phase-promoting complex/cyclosome activity [45]. Such
ReoT3D-induced alterations in the mitotic regulatory net-
work may reinforce the mitosis-arresting signal of taxanes,
leading to prolonged mitotic arrest and apoptosis. Better
understanding of the molecular consequences of ReoT3D
infection on cell cycle checkpoint function and apoptotic
signaling pathways in cancer cells will greatly enhance our
ability to design rational combination therapies with
proapoptotic oncolytic agent, ReoT3D, and various
classes of anticancer agents. Concurrently, it is also of high
importance to investigate potential consequences of
ReoT3D-chemotherapeutic combinations on normal tis-
sues in order to identify undesirable combination regi-
mens that are associated not only with synergistic
oncolytic activity, but also with enhanced toxicity in
humans.
Conclusion
The current study showed that the oncolytic activity of
ReoT3D could be most effectively potentiated by taxanes
through accelerated apoptosis, regardless of the level of
taxane-sensitivity. Recently, preliminary findings from
ongoing phase I clinical trials evaluating the safety of
ReoT3D-taxane combination in patients with chemother-
apy-refractory advanced tumors have demonstrated objec-
tive anticancer response in some patients without serious
side effects [46,47], corroborating that ReoT3D-taxane
combination regimens can achieve a durable oncolytic
effect in clinical settings and thus should be further
explored as a novel treatment modality for NSCLC.
Table 3: Summary of EM findings from survey of 100 adherent NCI-H23 cells
Cells with viral particles Multinucleated cells Nucleus
+ - Condensed chromatin Normal
None 0 100 6 2 98
Paclitaxel 1 μM0 1 0 0 2 2 1 1  ( 3 * ) 8 9
ReoT3D (MOI = 20) 37 63 3 4 (1*) 96
ReoT3D (MOI = 20) + Paclitaxel 1 μM 16 84 8 23 (17*) 77 (26§)
Note: NCI-H23 cells surveyed represent adherent cells that remained after exposure to the listed agents, alone or in combination, thus excluding 
detached dead cells. *Number of apoptotic cells characterized by condensed/fragmented chromatin, cytoplasmic shrinkage and vacuolation. 
§Number of mitotic cells. Abbreviations: EM, electron microscopy; ReoT3D, reovirus type 3 Dearing; MOI, multiplicity of infection.Molecular Cancer 2009, 8:47 http://www.molecular-cancer.com/content/8/1/47
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Methods
Cell lines, virus and chemotherapeutic agents
Human NSCLC cell lines included in the NCI-60 cell line
panel [48]: NCIH460 (large cell carcinoma), A549/ATCC
(adenocarcinoma), HOP-62 (adenocarcinoma), NCI-
H322M (bronchoalveolar carcinoma), NCI-H226 (squa-
mous cell carcinoma), EKVX (adenocarcinoma), NCI-
H23 (adenocarcinoma), NCI-H522 (adenocarcinoma),
and HOP-92 (large cell carcinoma) were obtained from
the In Vitro Cell Line Screening Program, DTP, NCI-Fred-
erick. Of the 9 cell lines, NCI-H460, A549/ATCC, HOP-
62, and NCIH23 have been found to have K-ras  gene
mutations [13]. L929 cells (mouse fibroblast L cells NCTC
clone 929) were obtained from American Type Culture
Collection (Manassas, VA). ReoT3D (REOLYSIN®) was
provided by Oncolytics Biotech Inc. (Calgary, AB Can-
ada). Cisplatin, paclitaxel, gemcitabine and vinblastine
were obtained through the Drug Synthesis and Chemistry
Branch, DTP, NCI.
Determination of virus- and drug-induced cell death
ReoT3D- or drug-induced CPE was assessed by the XTT
assay as described previously [49]. ED50 for ReoT3D was
defined as the initial virus dose (MOI expressed in pfu/
cell) that resulted in 50% cell viability at 48 hours post-
inoculation as compared to untreated controls. Sensitivity
of NSCLC cell lines to chemotherapeutic agents was
expressed as the drug concentration that inhibited cell
growth by 50% compared to untreated controls (IC50).
Both ED50 and IC50 were calculated by using the soft-
ware GraphPad Prism (GraphPad Software, Inc.). Cell via-
bility was also assessed by intracellular ATP content
(ATPLite™, PerkinElmer, Waltham, MA), when the level of
caspases activity was evaluated in selected NSCLC cell
lines treated with ReoT3D, paclitaxel or both agents in
combination (see below).
Evaluation of in vitro combination effects by the Chou-
Talalay method
The combined effects of ReoT3D and each chemothera-
peutic agent on cell survival were analyzed using the soft-
ware CalcuSyn (Biosoft, Ferguson, MO), which applies
the median-effect equation of Chou [16] and the CI equa-
tion of Chou and Talalay [17]. NCI-H460, HOP-92, NCI-
H23, EKVX, NCI-H226 and NCI-H322M plated in 96-well
microplates as above were exposed in triplicate to a serial
dilution of each agent or both in combination using the
constant ratio combination design [15] for 48 hours, fol-
lowed by the XTT assay for cell viability determination.
Calculated CIs were used to ascertain the presence of
strong synergism (CI < 0.3), moderate synergism (0.3 < CI
< 0.9), additive effect (CI = 1), antagonism (CI > 1) and
strong antagonism (CI > 3.3) [15] between ReoT3D and
chemotherapeutic agents.
Reovirus plaque assay
Levels of infectious progeny virions in culture superna-
tants produced from ReoT3D-infected NSCLC cells were
evaluated by plaque assay as previously described [50].
Infectious reovirus titers were expressed as pfu/mL of the
original sample.
Determination of activated Ras levels in NSCLC cells
Basal levels of activated Ras in 9 NSCLC cell lines were
determined by Ras activation assay Biochem Kit
(Cytoskeleton, Inc., Denver, CO) according to the manu-
facturer's instructions. Briefly, cell lysates were prepared
from NSCLC cells using the kit lysis buffer, and aliquots
of 2 mg protein were incubated with 20 μL of Raf1-RBD
beads at 4°C for 1 hr, followed by centrifugation to pellet
the Raf1-RBD beads. The pelleted beads were washed with
wash buffer twice, and resuspended in 10 μL Laemmli
sample buffer. The samples were separated by 12% Tris-
glycine SDS-PAGE, and subjected to Western blot analysis
with anti-Ras antibody (Cell Signaling Technology, Inc.,
Danvers, MA).
Western blot analysis of PARP cleavage
NSCLC cells were cultured overnight in 6-well plates at a
cell density of 2 × 106 cells/well, followed by incubation
with ReoT3D, chemotherapeutic agents (gemcitabine,
paclitaxel or vinblastine) or ReoT3D-chemotherapeutics
in combination at indicated concentrations. Twenty-four
to 30 hours after treatment, both adherent and non-
adherent cells were collected and lysed in 150 μL cell lysis
buffer (10 mM Tris/pH 7.4, 150 mM NaCl, 1 mM EDTA,
0.1% SDS, 1% sodium deoxycholate, 1% Triton X-100, 1
mM phenylmethylsulfonyl fluoride, 1 mM sodium
orthovanadate, 50 mM sodium fluoride, 10 μg/mL apro-
tinin, 1 μg/mL leupeptin and 5 μM pepstatin). Cell lysates
containing 20 μg protein were subjected to Western blot
analysis with anti-PARP (Cell Signaling Technology, Inc.)
and anti-β-actin (Cell Signaling Technology, Inc.) anti-
bodies.
Determination of caspase activity and ATP content by 
microplate-based assays
The levels of caspase activity and ATP content in NSCLC
cells treated with ReoT3D alone or in combination with
paclitaxel for 24 hours were evaluated by microplate-
based assays, using a fluorometric pan-caspase assay
(Homogeneous Caspases Assay; Roche Applied Science,
Indianapolis, IN) and luminescence ATP detection assay
(ATPLite™; PerkinElmer), respectively.
Flow cytometric analysis of DNA content and caspase-3 
activation
Adherent and non-adherent NSCLC cells harvested as
above (see Western blot analysis) were fixed and permea-
bilized with BD Cytofix/Cytoperm™ solution (BD Bio-Molecular Cancer 2009, 8:47 http://www.molecular-cancer.com/content/8/1/47
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sciences, San Jose, CA) and stained with FITC-conjugated
anti-active caspase-3 antibody (BD Biosciences), followed
by incubation with PI/RNase staining buffer (BD Bio-
sciences) for DNA content determination. The proportion
of cells expressing active caspase-3 and DNA content were
analyzed using a FACScan™ flow cytometer (BD Bio-
sciences) as previously described [51].
Transmission electron microscopy
NSCLC cells cultured in 6-well plates were processed in
situ for electron microscopic analysis as previously
described [52]. Thin sections (60 nm) were examined
with a Hitachi H7000 transmission electron microscope.
Statistical analysis
Results are reported as mean ± SD unless otherwise indi-
cated. Statistical significance of differences was deter-
mined by one-way ANOVA or Student's t-test as
appropriate. Differences were considered statistically sig-
nificant when P < 0.05 (two-tailed).
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